{"id":102883,"date":"2023-05-15T15:00:00","date_gmt":"2023-05-15T09:30:00","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=102883"},"modified":"2023-05-15T14:47:15","modified_gmt":"2023-05-15T09:17:15","slug":"pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/","title":{"rendered":"Pharma stock to BUY now for an upside of 28% after Morgan Stanley upgrades it to overweight"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3279964114\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>Shares of Lupin Ltd currently trading at the price of \u20b9788.65&nbsp; surged 2.78 percent on Monday by hitting a 52-week high of \u20b9800 or 16.77 percent.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3226325556\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>One of the probable reasons for the stock to hit a high price is the company&#8217;s recent announcement of strong Q4 FY 22-23 earnings.&nbsp;<\/p><p><strong>Based on an earnings call Morgan Stanley upgraded the stock to overweight and visibility of high-quality new product launches in this Fiscal year and recommended a target price of\u00a0\u20b9 918 or 28 percent upward on Lupin Ltd.<\/strong><\/p><p>Morgan Stanley anticipates free cash flow generation in FY23 and accepts a first-to-market position in several new launches of drugs such as gSpiriva, gDiazepam Gel, gNascobal Nasal Spray, and gDarunavir.<\/p><div class=\"trade-content_5\" id=\"trade-764962693\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>As per Consolidated financials of the previous quarter, <strong><a href=\"https:\/\/portal.tradebrains.in\/stock\/LUPIN\/consolidated\" target=\"_blank\" rel=\"noreferrer noopener\">Lupin&#8217;s<\/a><\/strong> operating revenues have increased by 2.5 percent from \u20b9 4,322 crores in Q3 to \u20b9 4,430 crores in Q4 FY23. Similarly, for\u00a0 YoY comparison, the revenues increased from \u20b9 16,405\u00a0 crores during FY 21-22 to \u20b9 16,641 crores in FY 22-23.\u00a0<\/p><p>The net profit of the company has slightly increased by 54 percent from&nbsp; \u20b9 157 crores in Q3 to&nbsp; \u20b9 242 crores in Q4, Similarly, for&nbsp; YoY comparison the net profit significantly increased from a loss of&nbsp; \u20b9&nbsp; 1,509&nbsp; crores during FY 21-22 to profit of&nbsp; \u20b9 447 crores in FY 22-23.<\/p><p>Lupin Ltd is engaged in the business of Manufacture of Pharmaceuticals, Lupin has a portfolio of over 200 products, including several complex generics and niche products. It is recognized as one of the world&#8217;s largest manufacturers of Tuberculosis drugs. The company has a significant market share across multiple therapy areas such as Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous Systems and etc. company has a presence in India, the USA, Australia, South Africa, Netherlands, Brazil, and Mexico.<\/p><p>The basic profitability ratios exhibiting operational efficiencies such as return on equity (ROE) and return on capital employed (ROCE) showed an upward trend in this financial year. ROE moved from -12.57&nbsp; percent during FY 21-22 to 3.45 percent in FY 22-23 and ROCE, keeping the time frame the same, moved from -9.07&nbsp; percent to 7.23 percent and the debt-equity ratio stands at 0.34.<\/p><p>In the past month, the stock has jumped around 17.41 percent ranging from&nbsp; \u20b9 658.15 to the current price levels.&nbsp;&nbsp;<\/p><p>According to the latest data pertaining to the shareholding pattern, the promoters hold a 47.08 percent stake, and Foreign Institutional Investors (FIIs) hold a 13.32&nbsp; percent stake in the company for FY 22-23.<\/p><div class=\"trade-content-10\" id=\"trade-378601873\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by Omkar C<\/strong><\/p><\/blockquote><h4 class=\"wp-block-heading\" id=\"h-disclaimer\"><strong>Disclaimer<\/strong><\/h4><div class=\"wp-block-image\"><figure class=\"aligncenter size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer.png\" alt=\"\" class=\"wp-image-26306\" width=\"256\" height=\"256\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.<\/strong><\/p><div class=\"trade-after-content\" id=\"trade-1244060533\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>Shares of Lupin Ltd currently trading at the price of \u20b9788.65&nbsp; surged 2.78 percent on Monday by hitting a 52-week high of \u20b9800 or 16.77 percent. One of the probable reasons for the stock to hit a high price is the company&#8217;s recent announcement of strong Q4 FY 22-23 earnings.&nbsp; Based on an earnings call [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":98971,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[9153,9151,770,5890,6617,948,936,9152],"class_list":["post-102883","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-lupin-gets-a-buy-call","tag-lupin-latest-news","tag-lupin-share","tag-pharma-stocks-latest-news","tag-pharma-stocks-to-buy-now","tag-stock-market","tag-stock-market-news","tag-why-is-lupin-going-up"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock to BUY now for an upside of 28% after Morgan Stanley upgrades it to overweight - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"Shares of the company currently trading at the price of \u20b9788.65\u00a0 surged 2.78 percent on Monday by hitting a 52-week high of \u20b9800 or 16.77 percent.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock to BUY now for an upside of 28% after Morgan Stanley upgrades it to overweight\" \/>\n<meta property=\"og:description\" content=\"Shares of the company currently trading at the price of \u20b9788.65\u00a0 surged 2.78 percent on Monday by hitting a 52-week high of \u20b9800 or 16.77 percent.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-15T09:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/\",\"name\":\"Pharma stock to BUY now for an upside of 28% after Morgan Stanley upgrades it to overweight - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"datePublished\":\"2023-05-15T09:30:00+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"Shares of the company currently trading at the price of \u20b9788.65\u00a0 surged 2.78 percent on Monday by hitting a 52-week high of \u20b9800 or 16.77 percent.\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock to BUY now for an upside of 28% after Morgan Stanley upgrades it to overweight\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock to BUY now for an upside of 28% after Morgan Stanley upgrades it to overweight - Trade Brains Features","description":"Shares of the company currently trading at the price of \u20b9788.65\u00a0 surged 2.78 percent on Monday by hitting a 52-week high of \u20b9800 or 16.77 percent.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock to BUY now for an upside of 28% after Morgan Stanley upgrades it to overweight","og_description":"Shares of the company currently trading at the price of \u20b9788.65\u00a0 surged 2.78 percent on Monday by hitting a 52-week high of \u20b9800 or 16.77 percent.","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2023-05-15T09:30:00+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/","name":"Pharma stock to BUY now for an upside of 28% after Morgan Stanley upgrades it to overweight - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","datePublished":"2023-05-15T09:30:00+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"Shares of the company currently trading at the price of \u20b9788.65\u00a0 surged 2.78 percent on Monday by hitting a 52-week high of \u20b9800 or 16.77 percent.","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/04\/pharma-cover-image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-to-buy-now-for-an-upside-of-28-after-morgan-stanley-upgrades-it-to-overweight\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock to BUY now for an upside of 28% after Morgan Stanley upgrades it to overweight"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/102883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=102883"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/102883\/revisions"}],"predecessor-version":[{"id":102884,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/102883\/revisions\/102884"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/98971"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=102883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=102883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=102883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}